Top Ten most popular articles on Pharmafile.com this week
pharmafile | January 12, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes
The Xmas break is now a distant memory as we move further into January, and with another Friday comes another rundown of the top ten most popular news stories with Pharmafile.com readers this week.
Among the top stories this week was the news that Shire is to split its business into two distinct units, Nestle could be the frontrunner in the competition to acquire Merck KGaA’s consumer health unit, and a remarkable once-weekly, slow-release HIV pill has been developed.
The crisis at Teva continues, as Teva execs, after making massive cuts to the global workforce, are now forced to put their hands in their own pockets and see their pay halved in order to cut costs for the company. But most popular this week was the news that ex-Novartis CEO David Epstein had secured executive positions at three new firms in just two days.
Check out the week’s ten most popular articles on Pharmafile.com now!
In order to improve antiretroviral treatment adherence, researchers from Brigham and Women’s Hospital and MIT have designed a pill that can be taken only once a week and is able to deliver medicine in appropriate amounts during the course of the week.
The signs were already there for Axovant Sciences’ key drug, intepirdine, when it posted poor results from a recent study back in September and the latest findings have confirmed the company’s fears, its candidate is a non-starter for the treatment of Alzheimer’s disease.
Researchers from RMIT University in Australia were tasked with developing a more effective breath test for determining what was happening in the digestive tract – they failed to develop a better test but did come up with a novel alternative.
It has been reported that Swiss food giant Nestle has pulled out in front as the top bidder for Merck KGaA’s consumer health business, allegedly offering up to $5 billion.
Shire has revealed that it now plans to move forward by separating its operations into two distinct divisions: rare disease and neuroscience.
Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge overturned the award to a couple accusing the pair of firms of failing to adequately warn patients of the internal bleeding risks of its blood thinner drug Xarelto.
Pfizer announced over the weekend that it would be backing out of research and development into the neuroscience area, abandoning a number of Phase 1 and 2 projects and removing a number of positions from the company.
As the pharmaceutical industry places increasing weight on the importance of patient-reported outcomes in securing approvals, Ben Hargreaves examines how this relationship can be mutually beneficial.
Teva’s current crisis has meant taking tough decisions; one such move seems to have been made by board members as they decided to cut their own pay packets whilst the crisis rumbles on.
Former CEO of Novartis Pharmaceuticals, David Epstein, has taken up the position of Chairman at Axcella Health, the same position at Rubius Therapeutics, and joined the Flagship Pioneering as an Executive Partner.
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …
On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo …